Pharmaceuticals, Biotechnology and Life Sciences
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue…
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that…
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to…
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare…
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has…
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million…
MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to…